News | May 04, 2026
Moderna posts Q1 2026 loss despite revenue surge
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
Lifts full-year outlook as obesity drug boom accelerates
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
Growth was broad-based across segments
Subscribe To Our Newsletter & Stay Updated
